# Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Study · id `cardio:ct-nct07023666` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07023666](<https://clinicaltrials.gov/study/NCT07023666>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07023666

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07023666. Allocation not applicable; no masking; primary purpose treatment. Start 2025-10-07 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07023666, source copy `cardio:ctgov-nct07023666-2026-09-09`, retrieved 2026-10-26)
- Started: 2025-10-07 (actual) (ClinicalTrials.gov record NCT07023666, source copy `cardio:ctgov-nct07023666-2026-09-09`, retrieved 2026-10-26)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07023666, source copy `cardio:ctgov-nct07023666-2026-09-09`, retrieved 2026-10-26)
- Completion: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT07023666, source copy `cardio:ctgov-nct07023666-2026-09-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07023666, source copy `cardio:ctgov-nct07023666-2026-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07023666-2026-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Early Screening and Treatment of Heart Complication in Sickle Cell Disease
- Condition: Sickle Cell Disease
- Intervention (Drug): Deferoxamine
- Intervention (Drug): Deferasirox
- Intervention (Drug): Deferiprone
- Intervention (Device): Echocardiography
- Intervention (Device): Electrocardiogram (ECG)
- Lead sponsor: Inova Health Care Services
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Inova Health Care Services (`cardio:org-inova-health-care-services`)

## Provenance

Content hash: 5cf4a9cf813ab559cebeb7120b12f19bd6bd1b27be404ed07272b075e934d409
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
